Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Jiangsu Aidea Pharmaceutical Group (688488.SH) announced that the company and its wholly-owned subsidiary, Luzhou Aide Pharmaceutical Technology Co., Ltd., have recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company to conduct clinical trials on a Class 1 new drug, ACC085 Injection, in the field of HIV/AIDS treatment. The announcement indicates that ACC085 is a newly developed HIV-1 capsid functional inhibitor with a novel chemical structure independently researched by the company. It is classified as a Class 1 chemical drug, which can directly bind to the interface between capsid protein subunits, inhibiting HIV-1 replication by interfering with multiple crucial steps in the virus life cycle (including capsid-mediated HIV-1 pre-viral DNA nuclear uptake, virus assembly and release, and capsid core formation).